The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients
Abstract
1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Woo, J.M.P.; Parks, C.G.; Jacobsen, S.; Costenbader, K.H.; Bernatsky, S. The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous. J. Intern. Med. 2022, 291, 755–778. [Google Scholar] [CrossRef]
- Pisetsky, D.S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 2023, 19, 509–524. [Google Scholar] [CrossRef]
- Iwata, S.; Tanaka, Y. Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus. Front. Med. 2022, 25, 849120. [Google Scholar] [CrossRef] [PubMed]
- Quaglia, M.; Merlotti, G.; De Andrea, M.; Borgogna, C.; Cantaluppi, V. Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses 2021, 13, 277. [Google Scholar] [CrossRef] [PubMed]
- Catalina, M.D.; Owen, K.A.; Labonte, A.C.; Grammer, A.C.; Lipsky, P.E. The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. J. Autoimmun. 2020, 110, 102359. [Google Scholar] [CrossRef]
- Ünlü, B.; Türsen, Ü.; Rajabi, Z.; Jabalameli, N.; Rajabi, F. Immunogenetics of Lupus Erythematosus. Adv. Exp. Med. Biol. 2022, 1367, 213–257. [Google Scholar] [CrossRef] [PubMed]
- Yap, D.Y.H.; Lai, K.N. Cytokines and Their Roles in the Pathogenesis of Systemic Lupus Erythematosus: From Basics to Recent Advances. J. Biomed. Biotechnol. 2010, 365083. [Google Scholar] [CrossRef] [PubMed]
- Jacob, N.; Stohl, W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res. Ther. 2011, 13, 228. [Google Scholar] [CrossRef]
- Talaat, R.M.; Alrefaey, S.A.; Bassyouni, I.H. Genetic polymorphisms of interleukin 6 and interleukin 10 in Egyptian patients with systemic lupus erythematosus. Lupus 2016, 25, 255–264. [Google Scholar] [CrossRef]
- Wu, Y.; Hsing, C.; Chiu, C.; Huang, H.; Hsu, Y. Roles of IL-1 and IL-10 family cytokines in the progression of systemic lupus erythematosus: Friends or foes? IUBMB Life 2022, 74, 143–156. [Google Scholar] [CrossRef]
- Peng, H.; Wang, W.; Zhou, M.; Li, R.; Pan, H.F.; Ye, D.Q. Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin. Rheumatol. 2013, 32, 1255–1266. [Google Scholar] [CrossRef]
- Godsell, J.; Rudloff, I.; Kandane-Rathnayake, R.; Hoi, A.; Nold, M.F.; Morand, E.F.; Harris, J. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci. Rep. 2016, 6, 34904. [Google Scholar]
- Gateva, V.; Sandling, J.K.; Hom, G.; Taylor, K.E.; Chung, S.A.; Sun, X.; Ortmann, W.; Kosoy, R.; Ferreira, R.C.; Nordmark, G.; et al. A large-scale replication study identifies TNIP1, PRDM1, Jazf1, UHRF1BP1 and IL-10 at risk loci for systemic lupus erythematosus. Nat. Genet. 2009, 41, 1228–1233. [Google Scholar] [CrossRef] [PubMed]
- Hofmann, S.R.; Rösen-Wolff, A.; Tsokos, G.C.; Hedrich, C.M. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin. Immunol. 2012, 143, 116–127. [Google Scholar] [CrossRef] [PubMed]
- Turnet, D.M.; Williams, D.M.; Sankaran, D.; Lazarus, M.; Sinnott, P.J.; Hutchinson, I.V. An investigation of polymorphism in the IL-10 gene promoter. Eur. J. Immunogenet. 1977, 24, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Karimabad, M.N.; Arababadi, M.K.; Hakimizadeh, E.; Daredori, H.Y.; Nazari, M.; Hassanshahi, G.; Kennedy, D. Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases? Inflammation. 2013, 36, 35–41. [Google Scholar] [CrossRef] [PubMed]
- Sakurai, D.; Zhao, J.; Deng, Y. Preferential binding to Elk-1by SLE associated Il-10 risk allele upregulates Il-10 expression. PloS Genet. 2003, 9, e1003870. [Google Scholar] [CrossRef]
- Chong, W.P.; Ip, W.K.; Wong, W.H.-S.; Lau, C.S.; Chan, T.M.; Lau, Y.L. Association of interleukin 10 promoter polymorphism with systemic lupus erythematosus. Genes Immun. 2004, 5, 484–492. [Google Scholar] [CrossRef] [PubMed]
- Palafox-Sánchez, C.A.; Oregon-Romero, E.; Salazar-Camarena, D.C.; Valle, Y.M.; Machado-Contreras, J.R.; Cruz, A.; Orozco-López, M.; Orozco-Barocio, G.; Mercado, M.V.-D.; Muñoz-Valle, J.F. Association of interleukin-10 promoter haplotypes with disease susceptibility and IL-10 levels in Mexican patients with systemic lupus erythematosus. ClinExp Med. 2015, 15, 439–446. [Google Scholar] [CrossRef]
- Wang, B.; Lu, J.S.; Yang, X.K.; Yuan, F.F.; Wang, H.; Lv, T.T.; Fan, Y.G.; Ye, D.Q. Association of single nucleotide polymorphism and haplotypes of interleukin-10 5’flanking region with systemic lupus erythematosus susceptibility in Han Chinese. Int. J. Clin. Exp. Pathol. 2017, 10, 2156–2162. [Google Scholar]
- Wang, G.H.; Zuo, T.; Zuo, Z.C. Impact of IL-10 gene polymorphisms and its interaction with environment on susceptibility to systemic lupus erythematosus. Int. J. Immunopathol. Pharmacol. 2020, 34, 2058738420945916. [Google Scholar] [CrossRef] [PubMed]
- Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19, 683–765. [Google Scholar] [CrossRef] [PubMed]
- Westendorp, R.G.; Langermans, J.A.; Huizinga, T.W.; Elouali, A.H.; Verweij, C.L.; Boomsma, D.I.; Vandenbrouke, J.P. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997, 349, 170–173. [Google Scholar] [CrossRef] [PubMed]
- Schotte, H.; Willeke, P.; Becker, H.; Poggemeyer, J.; Gaubitz, M.; Schmidt, H.; Schlüter, B. Association of extended interleukin 10 promoter haplotypes with diseases susceptibility and manifestations in German patients with systemic lupus erythematosus. Lupus 2014, 23, 378–385. [Google Scholar] [CrossRef] [PubMed]
- Wang, B.; Zhu, J.M.; Fan, Y.G.; Xu, W.D.; Cen, H.; Pan, H.F.; Ye, D.Q. Association of the -1082G/A polymorphism in the interleukin-10 gene with systemic lupus erythematosus: A meta-analysis. Gene 2013, 519, 209–216. [Google Scholar] [CrossRef] [PubMed]
- Nath, S.K.; Harley, J.B.; Lee, Y.H. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: A meta analysis. Hum. Gen. 2005, 118, 225–234. [Google Scholar] [CrossRef] [PubMed]
- Khoa, P.D.; Sugiyama, T.; Yokochi, T. Polymorphism of interleukin-10 promoter and tumor necrosis factor receptor II in Vietnamese patients with systemic lupus erythematosus. Clin Rheumatol. 2005, 24, 11–13. [Google Scholar] [CrossRef] [PubMed]
- Rosado, S.; Rua-Figueroa, I.; Vargas, J.A.; Garcia-Laorden, M.I.; Losada-Fernandez, I.; Martin-Donaire, T.; Perez-Chacon, G.; Rodriguez-Gallego, C.; Naranjo-Hernandez, A.; Ojeda-Bruno, S.; et al. Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands. Int. J. Immunogen. 2008, 35, 235–242. [Google Scholar] [CrossRef] [PubMed]
- Sobkowiak, A.; Lianeri, M.; Wudarski, M.; Łącki, J.K.; Jagodziński, P.P. Genetic variation in the interleukin-10 gene promotor in Polish patients with systemic lupus erythematosus. Rheum. Int. 2009, 29, 921–925. [Google Scholar] [CrossRef]
- Suárez, A.; López, P.; Mozo, L.; Gutiérrez, C. Differential effect of Il10 and TNF alfa genotypes on determining susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2000, 43, 129–134. [Google Scholar]
- Crawley, E.; Woo, P.; Isenberg, D.A. Single nucleotide polymorphic haplotypes of the Il10 5’flankingregion are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum. 1999, 42, 2017–2018. [Google Scholar] [CrossRef] [PubMed]
- Román-Fernández, I.V.; Machado-Contreras, J.R.; Muñoz-Valle, J.F.; Cruz, A.; Salazar-Camarena, D.C.; Palafox-Sánchez, C.A. Altered PTPN22 and IL10 mRNA Expression Is Associated with Disease Activity and Renal Involvement in Systemic Lupus Erythematosus. Diagnostics 2022, 18, 2859. [Google Scholar] [CrossRef] [PubMed]
- Hedrich, C.M.; Rauen, T.; Apostolidis, S.A.; Grammatikos, A.P.; Rodriguez, N.R.; Ioannidis, C.; Kyttaris, V.C.; Crispin, J.C.; Tsokos, G.C. Stat3 Promotes IL-10 Expression in Lupus T Cells through Trans-Activation and Chromatin Remodeling. Proc. Natl. Acad. Sci. USA 2014, 111, 13457–13462. [Google Scholar] [CrossRef] [PubMed]
- Csiszár, A.; Nagy, G.Y.; Gergely, P.; Pozsonyi, T.; Pócsik, E. Increased interferon-gamma (INF-γ), Il-10 and decreased Il-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2000, 122, 464–470. [Google Scholar] [CrossRef] [PubMed]
- Grammatikos, A.P.; Kyttaris, V.C.; Kis-Toth, K.; Fitzgerald, L.M.; Devlin, A.; Finnell, M.D.; Tsokos, G.C. A T Cell Gene Expression Panel for the Diagnosis and Monitoring of Disease Activity in Patients with Systemic Lupus Erythematosus. Clin. Immunol. 2014, 150, 192–200. [Google Scholar] [CrossRef] [PubMed]
- Vázquez-Villamar, M.; Palafox-Sánchez, C.; Muñoz-Valle, J.; Valle, Y.; Orozco-Barocio, G.; Hernández-Bello, J.; Oregon-Romero, E. Analysis of IL10 haplotypes in primary Sjögren’s syndrome patients from Western Mexico: Relationship with mRNA expression, IL-10 soluble levels, and autoantibodies. Hum. Immunol. 2015, 76, 473–479. [Google Scholar] [CrossRef] [PubMed]
- Im, S.-H.; Hueber, A.; Monticelli, S.; Kang, K.-H.; Rao, A. Chromatin-level regulation of the IL10 gene in T cells. J. Biol. Chem. 2004, 279, 46818. [Google Scholar] [CrossRef]
- Wang, Z.-Y.; Sato, H.; Kusam, S.; Sehra, S.; Toney, L.M.; Dent, A.L. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J. Immunol. 2005, 174, 2098. [Google Scholar] [CrossRef]
- Saraiva, M.; Christensen, J.R.; Tsytsykova, A.V.; Goldfeld, A.E.; Ley, S.C.; Kioussis, D. Identification of a macrophage-specific chromatin signature in the IL-10 locus. J. Immunol. 2005, 175, 1041. [Google Scholar] [CrossRef]
- Hedrich, C.M.; Ramakrishnan, A.; Dabitao, D.; Wang, F.; Ranatunga, D.; Bream, J.H. Dynamic DNA methylation patterns across the mouse and human IL10 genes during CD4+ T cell activation; influence of IL-27. Mol. Immunol. 2010, 48, 73. [Google Scholar] [CrossRef]
- Park, Y.B.; Lee, S.K.; Kim, D.S.; Lee, J.; Lee, C.H.; Song, C.H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 1998, 16, 283–288. [Google Scholar] [PubMed]
- Matilla, M.F.; García, E.G.; Comella, N.F.-L.; Verdejo, I.C.; Cortés, J.I.; Cuesta, J.A.C.; Ivorra, J.A.R. Increased interferon-1α, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus. Med. Clin. 2019, 153, 225–231. [Google Scholar]
- Petri, M.; Orbai, A.; Alarcón, G.S.; Gordon, C.; Merrill, J.T.; Fortin, P.R.; Bruce, I.N.; Isenberg, D.; Wallace, D.J.; Nived, O.; et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64, 2677–2686. [Google Scholar] [CrossRef] [PubMed]
N | SLE x ± SD | N | Control x ± SD | p | |
---|---|---|---|---|---|
Total | 67 | 11.92 ± 2.19 | 67 | 9.44 ± 1.69 | <0.0001 |
1082A/G | |||||
Co-dominant model | |||||
AA | 24 | 11.83 ± 1.61 | 18 | 9.67 ± 2.14 | <0.0001 |
AG | 29 | 11.69 ± 2.04 | 40 | 9.44 ± 1.66 | <0.0001 |
GG | 14 | 12.52 ± 3.22 | 9 | 9.02 ± 0.47 | <0.0001 |
Dominant model | |||||
AG+GG | 43 | 11.96 ± 2.48 | 49 | 9.36 ± 1.51 | <0.0001 |
Recessive model | |||||
AA+AG | 53 | 11.76 ± 1.84 | 58 | 9.51 ± 1.80 | <0.0001 |
Over-dominant model | |||||
AA+GG | 38 | 12.09 ± 2.32 | 27 | 9.45 ± 1.78 | <0.0001 |
819T/C | |||||
Co-dominant model | |||||
TT | 1 | 10.70 | 1 | 8.30 | - |
TC | 24 | 11.80 ± 2.35 | 23 | 9.75 ± 2.30 | <0.0001 |
CC | 42 | 12.01 ± 2.14 | 43 | 9.30 ± 1.28 | <0.0001 |
Dominant model | |||||
TC+CC | 66 | 11.93 ± 2.21 | 66 | 9.46 ± 1.70 | <0.0001 |
Recessive model | |||||
TC+TT | 25 | 11.76 ± 2.31 | 24 | 9.69 ± 2.27 | <0.0001 |
Over-dominant model | |||||
TT+CC | 43 | 11.98 ± 2.13 | 44 | 9.28 ± 1.27 | <0.0001 |
592A/C | |||||
Co-dominant model | |||||
AA | 1 | 10.70 | 1 | 8.30 | - |
AC | 24 | 11.80 ± 2.35 | 23 | 9.75 ± 2.30 | <0.0001 |
CC | 42 | 12.01 ± 2.14 | 43 | 9.30 ± 1.28 | <0.0001 |
Dominant model | |||||
AC+CC | 66 | 11.94 ± 2.21 | 66 | 9.46 ± 1.70 | <0.0001 |
Recessive model | |||||
AC+AA | 25 | 11.76 ± 2.31 | 24 | 9.69 ± 2.27 | <0.0001 |
Over-dominant model | |||||
AA+CC | 43 | 11.98 ± 2.13 | 44 | 9.28 ± 1.27 | <0.0001 |
Haplotype | |||||
ACC/ATA | 14 | 11.76 ± 1.95 | 10 | 9.76 ± 2.75 | 0.0031 |
GCC/GCC | 14 | 12.52 ± 3.22 | 9 | 9.02 ± 0.47 | <0.0001 |
GCC/ATA | 10 | 11.86 ± 2.94 | 13 | 9.75 ± 2.01 | 0.0032 |
GCC/ACC | 20 | 11.71 ± 1.49 | 27 | 9.29 ± 1.48 | <0.0001 |
ACC/ACC | 8 | 11.86 ± 0.89 | 7 | 9.73 ± 1.17 | 0.0059 |
ATA/ATA | 1 | 10.70 | 1 | 8.30 | - |
Secretion | |||||
Low | 23 | 11.75 ± 1.60 | 18 | 9.67 ± 2.14 | <0.0001 |
Intermediate | 30 | 11.76 ± 2.03 | 40 | 9.44 ± 1.66 | <0.0001 |
High | 14 | 12.52 ± 3.22 | 9 | 9.02 ± 0.47 | <0.0001 |
SLE n (%) | Control n (%) | OR | 95% CI | p* | |
---|---|---|---|---|---|
1082A/G | |||||
A | 77 (57%) | 78 (57%) | |||
G | 57 (43%) | 58 (43%) | 0.970 | [0.598–1.574] | 0.9018 |
Co-dominant model | |||||
AA | 24 (36%) | 18 (27%) | |||
GA | 29 (43%) | 40 (60%) | 0.544 | [0.250–1.181] | 0.1574 |
GG | 14 (21%) | 9 (13%) | 1.167 | [0.414–3.290] | |
Dominant model | |||||
AA | 24 (36%) | 18 (27%) | |||
GA+GG | 43 (64%) | 49 (73%) | 0.658 | [0.315–1.374] | 0.2639 |
Recessive model | |||||
AA+GA | 53 (79%) | 58 (87%) | |||
GG | 14 (21%) | 9 (13%) | 1.702 | [0.681–4.257] | 0.2520 |
Over-dominant model | |||||
AA+GG | 38 (57%) | 27 (40%) | |||
GA | 29 (43%) | 40 (60%) | 0.515 | [0.259–1.024] | 0.0573 |
X2 HWE (p) | 0.88 (0.348) | 3.13 (0.078) | |||
819T/C | |||||
C | 108 (81%) | 109 (81%) | |||
T | 26 (19%) | 25 (19%) | 1.050 | [0.570–1.932] | 0.8763 |
Co-dominant model | |||||
CC | 42 (63%) | 43 (64%) | |||
CT | 24 (36%) | 23 (34%) | 1.068 | [0.524–2.179] | 0.9836 |
TT | 1 (1%) | 1 (1%) | 1.024 | [0.062–16.921] | |
Dominant model | |||||
CC | 42 (63%) | 43 (64%) | |||
CT+TT | 25 (37%) | 24 (36%) | 1.067 | [0.528–2.154] | 0.8577 |
Recessive model | |||||
CC+CT | 66 (99%) | 66 (99%) | . | ||
TT | 1 (1%) | 1 (1%) | 1.000 | [0.061–16.325] | 1.0000 |
Over-dominant model | |||||
CC+TT | 43 (64%) | 44 (66%) | |||
CT | 24 (36%) | 23 (34%) | 1.068 | [0.525–2.171] | 0.8564 |
X2 HWE (p) | 1.41 (0.234) | 1.15 (0.284) | |||
592A/C | |||||
C | 108 (81%) | 109 (81%) | |||
A | 26 (19%) | 25 (19%) | 1.050 | [0.570–1.932] | 0.8763 |
Co-dominant model | |||||
CC | 42 (63%) | 43 (64%) | |||
CA | 24 (36%) | 23 (34%) | 1.068 | [0.524–2.179] | 0.9836 |
AA | 1 (1%) | 1 (1%) | 1.024 | [0.062–16.921] | |
Dominant model | |||||
CC | 42 (63%) | 43 (65%) | |||
CA+AA | 25 (37%) | 24 (35%) | 1.067 | [0.528–2.155] | 0.8577 |
Recessive model | |||||
CC+CA | 66 (99%) | 66 (99%) | |||
AA | 1 (1%) | 1 (1%) | 1.000 | [0.061–16.325] | 1.0000 |
Over-dominant model | |||||
CC+AA | 43 (64%) | 44 (66%) | |||
CA | 24 (36%) | 23 (33%) | 1.068 | [0.525–2.171] | 0.8564 |
X2 HWE (p) | 1.41 (0.234) | 1.15 (0.284) | |||
Haplotype | |||||
ACC/ATA | 14 (21%) | 10 (15%) | 0.664 | [0.272–1.623] | 0.3675 |
GCC/GCC | 14 (21%) | 9 (13%) | 0.860 | [0.293–2.524] | 0.7841 |
GCC/ATA | 10 (15%) | 13 (19%) | 1.372 | [0.555–3.390] | 0.4919 |
GCC/ACC | 20 (30%) | 27 (40%) | 1.586 | [0.776–3.245] | 0.2051 |
ACC/ACC | 8 (12%) | 7 (11%) | 0.860 | [0.293–2.524] | 0.7841 |
ATA/ATA | 1 (2%) | 1 (2%) | 1.000 | [0.061–16.326] | under 5 cases |
Secretion | |||||
Low | 23 (34%) | 18 (27%) | 0.703 | [0.336–1.472] | 0.3486 |
Intermediate | 30 (45%) | 40 (60%) | 1.827 | [0.920–3.627] | 0.0837 |
High | 14 (21%) | 9 (13%) | 0.587 | [0.235–1.469] | 0.2520 |
N | SLE x ± SD | N | Control x ± SD | p | |
---|---|---|---|---|---|
Total | 67 | 1333.7 ± 1567.2 | 67 | 644.5 ± 434.7 | <0.0001 |
1082A/G | |||||
Co-dominant model | |||||
AA | 24 | 875.42 ± 925.47 | 18 | 487.72 ± 249.74 | 0.0141 |
AG | 29 | 1355.55 ± 1221.31 | 40 | 682.53 ± 400.75 | <0.0001 |
GG | 14 | 2074.00 ± 2600.39 | 9 | 788.89 ± 746.50 | 0.0956 |
Dominant model | |||||
AG+GG | 43 | 1589.47 ± 1789.82 | 49 | 702.06 ± 474.44 | <0.0001 |
Recessive model | |||||
AA+AG | 53 | 1138.13 ± 1113.65 | 58 | 622.07 ± 369.80 | <0.0001 |
Over-dominant model | |||||
AA+GG | 38 | 1317.00 ± 724.30 | 27 | 588.11 ± 482.88 | 0.0021 |
819T/C | |||||
Co-dominant model | |||||
TT | 1 | 393.00 | 1 | 268.00 | - |
TC | 24 | 845.71 ± 892.74 | 23 | 695.22 ± 480.06 | 0.3922 |
CC | 42 | 1634.93 ± 1803.49 | 43 | 626.09 ± 413.58 | <0.0001 |
Dominant model | |||||
TC+CC | 66 | 1347.94 ± 1574.80 | 66 | 650.18 ± 435.46 | <0.0001 |
Recessive model | |||||
TC+TT | 25 | 827.60 ± 878.62 | 24 | 677.42 ± 477.54 | 0.3453 |
Over-dominant model | |||||
TT+CC | 43 | 1606.05 ± 1791.93 | 44 | 617.95 ± 412.29 | <0.0001 |
592A/C | |||||
Co-dominant model | |||||
AA | 1 | 393.00 | 1 | 268.00 | - |
AC | 24 | 845.71 ± 892.74 | 23 | 695.22 ± 480.06 | 0.3922 |
CC | 42 | 1634.93 ± 1803.49 | 43 | 626.09 ± 413.58 | <0.0001 |
Dominant model | |||||
AC+CC | 66 | 1347.94 ± 1574.80 | 66 | 650.18 ± 435.46 | <0.0001 |
Recessive model | |||||
AC+AA | 25 | 827.60 ± 878.62 | 24 | 677.42 ± 477.54 | 0.3453 |
Over-dominant model | |||||
AA+CC | 43 | 1606.05 ± 1791.93 | 44 | 617.95 ± 412.29 | <0.0001 |
Haplotype | |||||
ACC/ATA | 14 | 888.21 ± 1158.83 | 10 | 423.80 ± 137.95 | 0.0417 |
GCC/GCC | 14 | 2074.00 ± 2600.39 | 9 | 788.89 ± 746.50 | 0.0956 |
GCC/ATA | 10 | 786.20 ± 300.46 | 13 | 904.00 ± 547.38 | 0.6482 |
GCC/ACC | 20 | 1606.90 ± 1393.43 | 27 | 575.89 ± 257.45 | <0.0001 |
ACC/ACC | 8 | 936.63 ± 526.75 | 7 | 610.43 ± 340.21 | 0.3357 |
ATA/ATA | 1 | 393.00 | 1 | 268.00 | - |
Secretion | |||||
Low | 23 | 883.52 ± 945.40 | 18 | 487.72 ± 249.74 | 0.0175 |
Intermediate | 30 | 1333.33 ± 1206.22 | 40 | 682.53 ± 400.75 | <0.0001 |
High | 14 | 2074.00 ± 2600.39 | 9 | 788.89 ± 746.50 | 0.0956 |
Transcript Detected | Forward Primer (5′-3′) | Reverse Primer (5′-3′) | Accession Number |
---|---|---|---|
IL-10 mRNA | GGAGGAGGTGATGCCCCAAGCTGA | TGCTCCACGGCCTTGCTCTTGT | NM000572 |
18S rRNA | CAGTTATGGTTCCTTTGGTCGCTC | GTTGATAGGGCAGACGTTCGAATG | M10098 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Żak-Gołąb, A.; Cieślik, P.; Siekiera, U.; Kuśmierz, D.; Hrycek, A.; Holecki, M. The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients. Int. J. Mol. Sci. 2024, 25, 5511. https://doi.org/10.3390/ijms25105511
Żak-Gołąb A, Cieślik P, Siekiera U, Kuśmierz D, Hrycek A, Holecki M. The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients. International Journal of Molecular Sciences. 2024; 25(10):5511. https://doi.org/10.3390/ijms25105511
Chicago/Turabian StyleŻak-Gołąb, Agnieszka, Paweł Cieślik, Urszula Siekiera, Dariusz Kuśmierz, Antoni Hrycek, and Michał Holecki. 2024. "The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients" International Journal of Molecular Sciences 25, no. 10: 5511. https://doi.org/10.3390/ijms25105511
APA StyleŻak-Gołąb, A., Cieślik, P., Siekiera, U., Kuśmierz, D., Hrycek, A., & Holecki, M. (2024). The Impact of the IL-10 Gene Polymorphism on mRNA Expression and IL-10 Serum Concentration in Polish Lupus Patients. International Journal of Molecular Sciences, 25(10), 5511. https://doi.org/10.3390/ijms25105511